Patient characteristics and management according to the rate of switch by centre
| Switch rate 0–7% | Switch rate 7–18% | Switch rate 18–33% | Switch rate >33% | p Value (trend) | |
|---|---|---|---|---|---|
| Number of centres | 75 | 51 | 46 | 41 | |
| Number of patients | 454 | 1146 | 975 | 1061 | |
| Number of beds | 884±660 | 889±768 | 893±665 | 802±601 | 0.54 |
| Cathlab on site centres | 660 (67%) | 841 (73%) | 691 (71%) | 755 (71%) | 0.09 |
| Cardiac surgery on site | 320 (32%) | 521 (46%) | 533 (55%) | 372 (35%) | <0.001 |
| Hospital stay (days) | 8±7 | 7±7 | 8±7 | 8±7 | 0.65* |
| ICCU stay (days) | 5±4 | 4±4 | 4±4 | 4±4 | 0.35* |
| Switch (all) | 25 (1%) | 144 (13) | 254 (26) | 445 (42) | <0.001 |
| Switch (clopidogrel to prasugrel) | 15 (1.5%) | 108 (10) | 199 (21) | 256 (37) | <0.001 |
| Switch (prasugrel to clopidogrel) | 10 (1%) | 36 (3) | 55 (9) | 89 (13) | <0.001 |
| Male gender | 297 (65%) | 845 (74%) | 713 (73%) | 780 (73%) | 0.006 |
| Age | 66±14 | 64±14 | 64±14 | 64±14 | 0.12* |
| Elderly | 648 (34%) | 333 (29%) | 288 (30%) | 286 (27%) | 0.008 |
| GRACE risk score | 143±35 | 140±36 | 140±36 | 146±35 | 0.35* |
| LVEF | 54±11 | 51±11 | 50±11 | 52±12 | 0.15* |
| Body weight | 73±16 | 77±14 | 77±15 | 77±14 | 0.20* |
| Radial access | 570 (63%) | 763 (72%) | 715 (77%) | 847 (84%) | <0.001 |
| GPIIbIIIa | 284 (29%) | 410 (36%) | 345 (35%) | 460 (43%) | <0.001 |
| Coronary angiogram during stay | 912 (92%) | 1069 (93%) | 939 (96%) | 1021 (96%) | <0.001 |
| Reperfusion (STEMI) | 383 (76%) | 472 (76%) | 441 (80%) | 546 (84%) | <0.001 |
| Primary PCI (STEMI) | 320 (63%) | 367 (59%) | 384 (69%) | 430 (66%) | 0.001 |
| Thrombolysis (STEMI) | 34 (3.4%) | 64 (5.6%) | 39 (4.0%) | 68 (6.4%) | 0.01 |
| DAPT at discharge | 812 (85%) | 980 (88%) | 826 (88%) | 911 (89%) | 0.01 |
| β-Blockers at discharge | 834 (87%) | 967 (87%) | 797 (85%) | 898 (88%) | 0.29 |
| ACEI at discharge | 595 (62%) | 809 (73%) | 659 (70%) | 1024 (76%) | <0.001 |
| Statins at discharge | 863 (90%) | 1018 (91%) | 872 (93%) | 950 (93%) | 0.002 |
| Composite score | 0.76±0.24 | 0.80±0.22 | 0.81±0.21 | 0.82±0.20 | <0.001* |
| Composite score (STEMI) | 0.83±0.15 | 0.84±0.14 | 0.84±0.14 | 0.85±0.13 | <0.02* |
| BARC 3A | 18 (1.8%) | 26 (2.3%) | 9 (0.9%) | 13 (1.2%) | 0.06 |
| BARC 3B | 22 (2.2%) | 34 (3.0%) | 13 (1.3%) | 25 (2.4%) | 0.53 |
| BARC 3C | 0 | 1 (0.1%) | 0 | 1(0.1%) | 0.52 |
| Transfusion | 39 (3.9%) | 41 (3.6%) | 30 (3.1%) | 25 (2.4%) | 0.03 |
| Hb drop of 3–5 g/dL | 81 (8.2%) | 79 (6.9%) | 79 (8.1%) | 77 (7.3%) | 0.67 |
| Hb drop≥5 g/dL | 21 (2.1%) | 27 (2.9%) | 12 (1.2%) | 21 (1.9%) | 0.41 |
| In-hospital mortality | 25 (2.5%) | 33 (2.9%) | 34 (3.5%) | 33 (3.1%) | 0.33 |
| Stent thrombosis | 4 (0.4%) | 6 (0.5%) | 6 (0.6%) | 5 (0.5%) | 0.79 |
| Reinfarction | 10 (1.0%) | 9 (0.8%) | 9 (0.9%) | 16 (1.5%) | 0.23 |
| Combined end point | 49 (5.0%) | 66 (5.7%) | 51 (5.2%) | 70 (6.6%) | 0.17 |
*Jonckheere-Terpstra test for quantitative variables.
ACEI, ACE inhibitor; BARC, Bleeding Academic Research Consortium; Cathlab, catheterisation laboratory; DAPT, dual antiplatelet therapy; GRACE, Global Registry of Acute Coronary Events; GPIIbIIIa, glycoprotein IIb/IIIa inhibitor; Hb, haemoglobin; ICCU, intensive cardiac care unit; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; STEMI, ST segment elevation myocardial infarction.